| Stereochemistry | RACEMIC |
| Molecular Formula | C25H26F2N6OS |
| Molecular Weight | 496.575 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(CSC1=NC=NC2=C1N=CN2)CN3CCN(CC3)C(C4=CC=C(F)C=C4)C5=CC=C(F)C=C5
InChI
InChIKey=JOMBZLFCXNSKEQ-UHFFFAOYSA-N
InChI=1S/C25H26F2N6OS/c26-19-5-1-17(2-6-19)23(18-3-7-20(27)8-4-18)33-11-9-32(10-12-33)13-21(34)14-35-25-22-24(29-15-28-22)30-16-31-25/h1-8,15-16,21,23,34H,9-14H2,(H,28,29,30,31)
Carsatrin (also known as RWJ 24517) is purinylpiperazine derivative patented by Ortho Pharmaceutical Corp. as cardiotonic and antiarrhythmic. Carsatrin acts as positive inotropic agent that increases twitch tension and prolongs the action potential (AP) duration of ventricular muscle without affecting the Na+,K+-ATPase, adenylyl cyclase, phosphodiesterase isozymes, or cardiac myofilaments. Carsatrin’s positive inotropic effect can be prevented by tetrodotoxin but not by the adrenergic antagonists timolol, yohimbine, or prazosin
Originator
Approval Year
PubMed
Patents
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
